Contents
47 — RNA-seq Part 10 — Functional genomics

47 — RNA-seq

Before this: Ch 06 · Ch 42 · Ch 44 · Time: ~55 min

Statistics needed: S2 Distributions · S4 Hypothesis testing · S5 Variance and regression · S7 High-dimensional data

Chapter 46 asked what sequence a genome contains. This chapter asks a different question: which parts of it are being read, and how much. The answer is a matrix of counts, and almost every mistake made with that matrix comes from forgetting what the counts actually are.

What you'll be able to do

The core idea

A sequencer does not measure concentration. It draws a fixed-size sample of fragments from a pool and tells you what it drew. If you sequence 30 million fragments, you get 30 million fragments — whether the library came from a cell containing 200,000 mRNA molecules or 800,000.

So the count for gene i in sample j is, to a first approximation, a multinomial draw:

K_ij  ~  Multinomial( N_j ,  p_·j )        with   p_ij  =  l̃_i θ_ij / Σ_k l̃_k θ_kj

where θ is the relative molar abundance, l̃ the effective length (a longer molecule breaks into more fragments, so it is over-sampled), and N_j the library size — a machine parameter, not a biological one.

Everything in this chapter follows from one property of that expression: the p's sum to one. data are compositional. They live on a simplex, they carry no information about absolute scale, and a change in one gene mechanically changes the measured value of every other gene. Fail to correct for that and you will read the arithmetic of the simplex as biology. That is the single most common error in the field, and it is not subtle: it can produce thousands of confidently "downregulated" genes that did not change at all.


1. Design decides what is answerable

No analysis recovers information the design threw away. Two distinctions come first.

Biological replicates are independent biological units — different animals, different donors, independently treated cultures. They capture the variance you want to generalise over. Technical replicates are the same RNA sequenced twice, or the same library split across lanes. They capture only machine noise, which in is close to Poisson and therefore almost negligible. Sequencing one sample five times gives you n = 1, no matter how the software labels the columns.

n = 3 is a convention, not a justification. Two is the bare minimum for any within-group variance estimate at all; three is the smallest group size that gives more than a single residual degree of freedom after fitting a mean, and it is what fits a budget. It is not the output of a power calculation, and for a typical biological coefficient of variation it detects only large fold changes.

Replicates beat depth, and you can prove it

For a gene with mean count μ and α (defined in §6, with Var(K) = μ + αμ²), the delta method gives Var(log K) ≈ Var(K)/μ² = 1/μ + α. Average over n replicates and the variance of the group mean on the log scale is (1/μ + α)/n, so

Var( log2 FC )  ≈  (1/ln2)² · (1/n₁ + 1/n₂) · ( 1/μ + α )
                                              └────┬────┘
                          depth shrinks this term only, and only toward α

Depth raises μ, which attacks the 1/μ term and nothing else. That term has a floor of zero; the dispersion α does not move. Replication divides the whole expression by n, with no floor.

Statistics: the mean–variance relation Var = μ + αμ², and why counts across biological replicates need it, are covered in S2 §5.

Concretely, at α = 0.04 (a 20% biological CV — typical of cell lines or inbred animals; human donor tissue more often runs at a BCV near 0.4, i.e. α ≈ 0.16, which only strengthens the conclusion by moving the crossover down to μ ≈ 6): at μ = 25 the two terms are equal. Quadrupling depth to μ = 100 cuts the variance by 37%. Quadrupling it again, and again forever, buys you the remaining 20%. Going from n = 3 to n = 6 halves it outright. Once the mean count per sample is comfortably above ~100 — which is where most expressed genes sit at conventional depths of roughly 20–30 million reads per sample — spend the next dollar on another biological replicate. The exception is isoform-level or low-expression work, where many genes are still in the 1/μ-dominated regime.

Batch must not be confounded with condition

If every control was prepared on Monday and every treated sample on Tuesday, the design matrix has two collinear columns and the condition coefficient is not identifiable. This is not a statistical subtlety to be handled with a clever correction; it is a rank deficiency, and no amount of downstream software repairs it.

CONFOUNDED (unfixable)              BLOCKED (fixable)
sample cond batch                   sample cond batch
S1     ctrl  1                      S1     ctrl  1
S2     ctrl  1                      S2     trt   1
S3     ctrl  1                      S3     ctrl  2
S4     trt   2                      S4     trt   2
S5     trt   2                      S5     ctrl  3
S6     trt   2                      S6     trt   3
                                    → ~ batch + condition estimates both

in RNA-seq are large — often larger than the biology. Extraction day, kit lot, technician, flow cell and RIN all leave signatures. Two remedies, in order of preference: block (every batch contains every condition, so batch enters the model as a factor and its effect is absorbed), or randomise (assign samples to batches at random, so the confound becomes noise rather than bias). Randomisation is the fallback for nuisance variables you did not think of. Blocking is better for the ones you did.

2. Library preparation is a measurement choice

Total RNA is >80% ribosomal RNA. Sequencing it directly wastes almost all your depth, so every protocol begins by choosing what to keep — and that choice defines what the experiment can see.

Poly-A selectionrRNA depletion
CapturesPolyadenylated RNA — mostly mature mRNAEverything except rRNA: mRNA, , pre-mRNA, circRNA, histone mRNAs
Depth efficiencyHigh; most reads are exonic mRNALower; a large intronic and non-coding fraction
RNA quality neededHigh — degradation truncates from the 5' endTolerant; works on FFPE and degraded input
Blind toNon-polyadenylated transcripts, most nascent RNA, bacterial RNALittle, but at a cost in mRNA reads
Choose whenStandard mRNA , good-quality inputDegraded/clinical material, lncRNA or nascent , prokaryotes

Strandedness. In an unstranded library the read gives you a locus but not which strand the original RNA came from. That is fine until two genes overlap on opposite strands — which happens thousands of times in a mammalian genome — at which point every read in the overlap is ambiguous and either discarded or misassigned. It is fatal for antisense transcripts, whose entire identity is "the same locus, other strand". Stranded protocols mark the original strand chemically. There is no reason to generate unstranded data.

. A unique molecular identifier is a random barcode attached to each cDNA molecule before amplification. Two reads sharing a UMI and a position came from one original molecule. This matters more than in DNA sequencing, because in coordinate are expected: a short, highly expressed transcript will be covered by identical fragments legitimately. Deduplicating RNA-seq by coordinate alone, the DNA convention, removes real signal. The UMI must be long enough that same-position collisions are rare given the number of molecules there — a birthday-problem calculation, not a guess.

3'-biased protocols sequence only the 3' end of each molecule. One read then approximates one molecule: no length is needed, and applying it is actively wrong. The price is losing all isoform information and becoming sensitive to alternative polyadenylation and to the accuracy of annotated 3' ends. This is the design used by most droplet single-cell assays (Ch 48).

3. From reads to counts

graph LR R["reads<br/>FASTQ"] --> A["spliced alignment<br/>to genome"] R --> S["selective alignment<br/>to transcriptome + decoys"] A --> C["count per gene<br/>using annotation"] S --> E["EM over transcripts"] E --> T["transcript estimates"] T --> G["sum to gene level"] C --> M["count matrix<br/>genes x samples"] G --> M

Alignment-based counting maps reads to the genome with a spliced aligner — one that can place a gap of tens of kilobases and score it as an rather than a deletion (Ch 42) — then counts reads overlapping each gene's exons under a stated rule for ambiguity. Its virtue is that reads from unannotated regions remain visible, which is what you want if the is incomplete or you care about intronic signal.

Lightweight / selective alignment skips base-level alignment for most reads by matching k-mers against a transcriptome index, then scores the surviving candidates well enough to reject spurious matches. The two failure modes it must defend against are instructive: pure k-mer compatibility over-calls, so a score is still required; and reads originating from sequence not in the transcriptome (introns, unannotated loci, genomic DNA) get force-assigned to whatever transcript they least badly resemble. The fix is decoy sequence — include the genome in the index so the model has a "none of the above" option. Both points are the same point: a model with no null class will explain everything.

Multi-mapping and EM

Most reads are compatible with several transcripts of the same gene, because those transcripts share exons. The assignment is latent; the abundances are the parameters. That is the structure of expectation–maximisation, and it is spelled out below.

       exon1        exon2        exon3
tx A   ▓▓▓▓▓▓▓▓ ─── ▓▓▓▓▓▓▓▓ ─── ▓▓▓▓▓▓▓▓
tx B   ▓▓▓▓▓▓▓▓ ─────────────────▓▓▓▓▓▓▓▓     (skips exon2)

read classes:   unique to A  (spans e1–e2 junction, or lies in e2)
                unique to B  (spans e1–e3 junction)
                shared       (lies inside e1 or e3)

With θ_t the abundance of transcript t and P(r | t) the probability of generating read r from it (∝ 1/l̃_t for a uniform fragment model, times alignment and fragment-length terms):

E-step   γ_rt  =  θ_t P(r|t)  /  Σ_u θ_u P(r|u)          responsibility
M-step   c_t   =  Σ_r γ_rt ,      θ_t  ∝  c_t / l̃_t      re-estimate

The unique reads identify the mixture; the shared reads are then allocated in proportion to it. Take equal effective lengths, 80 reads unique to A, 20 unique to B, 100 shared. At the fixed point, let f be A's share: c_A = 80 + 100f and the total is 200, so f = (80 + 100f)/200, giving f = 0.8, c_A = 160, c_B = 40. The shared reads split 80:20 because that is what the unique reads said the mixture was.

Because the assignments are inferred, transcript-level estimates carry inferential uncertainty on top of sampling noise — which is why quantifiers report bootstrap or Gibbs replicates. Two isoforms differing by one short exon are nearly unidentifiable, and their estimates are strongly anticorrelated.

Gene level versus transcript level. GENCODE Release 50 annotates 644,292 transcripts across 78,733 genes (verified-facts) — over eight per gene, many differing by a cassette exon or an alternate 3' end. Summing transcript estimates to the gene cancels most of that anticorrelated error, so gene-level counts are markedly more robust for . Go to transcript level when the question is genuinely about isoforms (§8), not by default.

4. Normalisation: the conceptual heart

Three distinct problems get conflated under one word.

Depth. Sample A got 40M reads, sample B got 20M. Trivially fixable by scaling — and this is the only part most people think is.

Length. A 10 kb transcript yields ~10× the fragments of a 1 kb transcript at equal molar abundance. This matters when comparing different genes within one sample. It does not matter when comparing the same gene across samples, because the length cancels. Length correction is a within-sample operation, and applying it before a between-sample test adds noise for nothing.

Composition. The hard one. Since Σp = 1, one gene rising must push every other measured fraction down. Total-count scaling assumes the total is a stable reference — which is exactly the assumption composition violates.

Why total-count scaling fails

Five genes, equal lengths. In the control each is at 1,000 molecules per cell (total 5,000). In the treated sample, gene E rises 6-fold to 6,000 and nothing else changes (total 10,000). Sequence 10,000 reads from each:

gene    ctrl     treat        truth
A       2000     1000         unchanged
B       2000     1000         unchanged
C       2000     1000         unchanged
D       2000     1000         unchanged
E       2000     6000         6x up
total  10000    10000

Divide by the total and you conclude that four of five genes halved and E rose 3-fold. Every one of those five conclusions is wrong. The library size was never a measurement of anything; it was a setting on the machine.

Robust size factors

The fix is to estimate the scale from the typical gene rather than the sum, under the assumption that most genes are not differentially expressed. Two constructions dominate.

Median-of-ratios. Build a reference pseudo-sample as the per-gene geometric mean across samples; take each sample's ratio to it gene by gene; the size factor is the median ratio. The median is what makes it robust — a minority of genes moving hard cannot drag it.

Trimmed mean of M-values (TMM). Against a reference sample, compute per-gene log ratios (M) and average log intensities (A), trim the extremes of both, and take a precision-weighted mean of the surviving M values. Same logic, different estimator: discard the tails and read the scale off the bulk.

Both estimate a single scalar per sample, fed to the model as an offset — not as a divisor applied to the counts, because the count must stay an integer for the likelihood to be a count likelihood.

Both rest on the same assumption: most genes do not change, and those that do are not all in the same direction. When that fails — a global transcriptional amplification, a inhibitor, a MYC-amplified tumour compared to normal tissue — no computational normalisation can save you, because the data are genuinely non-identifiable. The only fix is external: spike-in RNA added per cell or per unit mass, or an independent cell count.

CPM, TPM, FPKM — and where they belong

UnitDefinitionCorrects forSums to
CPMKᵢ / N × 10⁶depth10⁶
FPKM/RPKMKᵢ / (l̃ᵢ/10³ · N/10⁶)depth, lengtha sample-specific constant
rᵢ / Σrⱼ × 10⁶, where rᵢ = Kᵢ / l̃ᵢlength then depth10⁶ always

The difference between TPM and FPKM is the order of operations. FPKM divides by depth first, then by length; TPM converts to rates first, then normalises those rates to sum to a million. Because TPM's denominator is the sum of rates in that sample, TPM has the same unit in every sample — a share of a million transcripts — whereas FPKM's normalising constant is sample-specific, so only TPM values are even on a common scale. Note the word scale: neither unit is composition-corrected. TPMs sum to 10⁶ by construction, so a global shift distorts every TPM exactly as it distorts counts-over-total — run the five-gene example above through TPM and it reports the four unchanged genes as halved, the same error.

Three genes in one sample:

gene   count   eff.len   rate = count/len     TPM              FPKM
A       1000     2000       0.5              185,185         294,118
B        500      250       2.0              740,741       1,176,471
C        200     1000       0.2               74,074         117,647
                       Σ = 2.7      Σ = 1,000,000      Σ = 1,588,235

(Three genes, so the values are absurdly large; with ~20,000 expressed genes TPMs run from below 1 to a few thousand.) Note that gene A has twice B's reads but a quarter of its molar abundance — that is the length correction doing its job. And note the FPKM column sums to 1,588,235, a number specific to this sample: change the expression profile and the unit changes underneath you.

None of these belongs in a test. They are per-sample rescalings designed for human reading and cross-gene comparison. Feeding them to a DE model destroys the information the model needs — the counts themselves, whose magnitude encodes precision. A gene at TPM 50 measured from 5 reads and the same gene measured from 5,000 reads are the same number with wildly different reliability, and the model can no longer tell. Test on raw counts with size factors as offsets. Report TPM.

5. Differential expression

Why not Poisson

Technical resampling of a fixed library is close to Poisson: Var = mean. Biological replicates are not, because the underlying relative abundance θ itself varies between individuals. Mixing a Poisson rate over a gamma distribution gives exactly a :

K_ij ~ NB( mean = s_j μ_i ,  Var = s_jμ_i + α_i (s_jμ_i)² )

The α is the squared coefficient of variation of the true abundance across replicates. The NB is not a fudge factor for "extra noise" — it is the precise consequence of Poisson sampling of a randomly varying rate. Using Poisson understates the variance of every gene and produces p-values that are wrong by orders of magnitude.

Dispersion estimation is where the statistics happens

With n = 3 you have about two degrees of freedom per gene. A per-gene dispersion estimate from that is nearly worthless, and the errors are asymmetric: genes that happen to look quiet get a tiny α and become spurious hits. The solution is information sharing across genes — fit a smooth mean–dispersion trend across all 20,000 genes, then shrink each gene's noisy estimate toward the trend, empirical-Bayes style. Genes with genuinely, robustly high dispersion are detected as outliers and not shrunk, so real variability is preserved. This is the step that makes small-n work at all.

Statistics: shrinking a noisy per-gene estimate toward a trend fitted across all genes is the shrinkage of S7 §6; §7 works this exact case on real counts.

The GLM

log( E[K_ij] )  =  log s_j  +  x_j'β_i

A log-link NB GLM, with log size factor as an offset (coefficient fixed at 1, not estimated). Design matrices, and what a coefficient means once other terms are in the model, are covered in S5 §6; the same structure transfers here: ~ batch + condition for a blocked design, ~ subject + timepoint for paired samples, ~ genotype * treatment when the question is whether the treatment effect differs by , contrasts for specific comparisons. Significance comes from a Wald test on β or a likelihood-ratio test between nested designs; the LRT is the right tool when the alternative involves several coefficients at once, such as "any difference across four timepoints".

Shrink the fold changes too

The raw log fold change for a gene with counts 3 versus 0 is enormous and meaningless. Its sampling variance is huge, and if you rank by raw LFC the top of your list is entirely such genes. Applying a zero-centred prior and reporting the MAP estimate shrinks low-information LFCs toward zero while leaving well-measured ones essentially untouched. Shrunken LFCs are the ones to rank, plot and threshold.

Multiple testing

Benjamini–Hochberg on ~20,000 genes, controlling FDR rather than FWER, because the goal is a list worth following up, not a guarantee of zero errors.

Statistics: the false discovery rate, the Benjamini–Hochberg procedure, and why FDR rather than FWER is the right target for a are covered in S7 §3.

Independent filtering removes genes with no chance of detection — typically those with very low mean normalised count — before BH. This is not p-hacking, and the reason it is legitimate is precise: the filter statistic (mean count across all samples, ignoring the condition labels) is independent of the p-value under the null, so filtering on it does not distort the null distribution of the survivors. It does reduce the number of tests, which reduces the BH penalty, which increases power for everything that remains. The independence condition is the whole justification — filter on something correlated with the test statistic under the null and you have simply cheated.

Significance is not effect size

A gene expressed at 50,000 counts is measured so precisely that a fold change too small to care about can still clear significance; a gene at 40 counts with a genuine 4-fold change may not clear FDR at all. Precision scales with count — the 1/μ term in Var(log2 FC) is negligible for the first gene and not for the second, and low-count genes sit higher on the mean–dispersion trend besides. Ranking by p-value ranks partly by expression level. Report both, threshold on both, and if a minimum effect size actually matters, put it in the null hypothesis — test H₀: |LFC| ≤ τ rather than filtering the results of a point-null test afterwards, which does not control anything.

6. Looking at the matrix before believing it

Transform before you project. Raw counts have mean-dependent variance, so a on them is dominated by the most highly expressed genes. log(x + 1) overcorrects: low counts become enormously noisy on the log scale. Use a variance-stabilising or regularised-log transform, which makes variance roughly constant across the mean range, then do PCA, correlation heatmaps and hierarchical clustering on that.

PCA is the batch detector. If PC1 separates by extraction day rather than by condition, you have learned something crucial before running a single test. Sample–sample distance matrices catch swapped labels and outlier libraries the same way.

Statistics: PCA — the eigenvectors of a sample–sample matrix, and how much variance each axis carries — is covered in S7 §5.

Enrichment analysis turns a gene list into a sentence about biology, and it has known biases.

Over-representation (ORA)Gene set enrichment (GSEA)
InputA thresholded list of significant genesAll genes, ranked by a statistic
TestHypergeometric / Fisher against a background universeRunning-sum enrichment statistic, permutation null
StrengthSimple, interpretableDetects coordinated small shifts; no arbitrary cutoff
WeaknessThreshold-sensitive; discards the rankingSensitive to the ranking metric

Shared biases, which matter more than the choice between them: detection power scales with expression and gene length, so sets full of long, highly expressed genes (ribosomal, mitochondrial, extracellular matrix) come up over and over; the background universe must be the set of genes actually testable in your experiment, not all annotated genes; gene sets overlap heavily, so the tests are correlated and the FDR is optimistic; and is biased toward well-studied genes, so enrichment analysis partly rediscovers the history of the literature.

7. Beyond one number per gene

. Three different questions, often confused: differential gene expression (total output changed), differential transcript expression (one isoform's absolute level changed), and differential transcript usage (the isoform proportions changed with total output constant). DTU is usually the biologically interesting one and is invisible to gene-level analysis. Event-level methods sidestep isoform reconstruction by quantifying a local ratio — percent spliced in, PSI = inclusion / (inclusion + exclusion) — from junction-spanning reads, which is well-determined even when the full isoform set is not. With short reads, reconstructing full-length isoforms from fragments is genuinely underdetermined; long reads (Ch 40) sequence whole molecules and largely dissolve the problem.

-specific expression. Within one heterozygous individual, count reads carrying each allele at a het site. The two alleles share a nucleus, a trans environment and a cell — so a consistent imbalance isolates a cis-acting effect with a perfect internal control. The trap is : reads carrying the alternate allele align slightly worse, so the reference allele is systematically over-counted. Mitigate with a personalised reference, masked sites, or a graph (Ch 45).

. Treat normalised expression of each gene as a and regress it on dosage across individuals — the same machinery as Ch 51, applied to a molecular . Test variants in a cis window around the gene, correct within gene then across genes, and include genotype PCs plus latent factors estimated from the expression matrix itself as covariates, because unmodelled batch structure inflates eQTL discovery spectacularly. Ch 52 uses this to connect signals to genes.

. A bulk profile is a mixture: y ≈ Σ_c w_c · x_c, with w the cell-type proportions and x a reference signature matrix — a non-negative, sum-to-one constrained regression. This is not a niche technique but a correction for a fundamental confound: a gene "upregulated" in bulk tissue may simply reflect more of a cell type that always expressed it. Inflammation changes cell composition; so does development, so does treatment. Bulk DE cannot distinguish composition from per-cell regulation without either deconvolution or single-cell data (Ch 48).

8. Failure modes, and how each announces itself

FailureSignature in QCConsequence
Degraded RNA (3' bias)Gene-body sloped toward the 3' end; low RIN/DV200; long genes lose coverage firstLength becomes wrong; long genes look down; isoform assignment corrupted
rRNA carryoverHigh fraction of reads on rRNA lociEffective depth is only the non-rRNA depth; a 50% rRNA library is half the experiment you paid for
Genomic DNA carryoverElevated intergenic and uniform intronic coverage; in a stranded library, reads with no strand preferenceInflates counts for long genes, since gDNA reads scale with genomic span
Global shift read as biologyHalf the genome "significantly down" at similar fold changesA composition artefact from a genuine change in total RNA per cell — see §4
gene-body coverage, 5' → 3'
intact RNA    ▁▃▅▆▇▇▇▇▇▇▇▆▅▃▁       roughly uniform
degraded      ▁▁▁▂▂▃▄▅▆▇▇▇▇▇       3' end retained (poly-A capture pulls from the tail)

Common misconceptions

What people thinkWhat's actually true
means dividing by library sizeLibrary size is the easy part. Composition is the hard part, and total-count scaling gets it exactly wrong when a few genes dominate
More sequencing depth means a better DE experimentVar(log FC) ≈ (1/n₁ + 1/n₂)(1/μ + α) — 2/n with equal groups. Depth attacks only 1/μ and saturates at α; replicates divide everything by n. Past ~100 counts per gene, buy replicates
is the normalised value, so it's what you test onTPM is a per-sample rescaling for reading and cross-gene comparison. It discards the count magnitude that encodes precision. Test on counts with size-factor offsets
Counts are Poisson, so a Poisson test is rightPoisson covers technical resampling only. Biological replicates vary in the underlying rate, giving a gamma–Poisson mixture — a . Poisson p-values are wrong by orders of magnitude
can be removed after the factOnly if batch and condition are not confounded. If they are, the design matrix is rank-deficient and the effect is not identifiable — no correction exists
should be removed, as in DNA-seqIn , coordinate duplicates are expected for short, highly expressed transcripts. Without , coordinate deduplication deletes real signal
The top of a p-value-sorted list is the most changed genesIt is partly a list of the most highly expressed genes. Significance and effect size are different quantities; report and threshold both
Half the genome went down, so the treatment is a global More often the treatment raised total RNA per cell and the simplex did the rest. Distinguishing the two requires spike-ins or cell counts, not more analysis
A gene up in bulk tissue is up in the cellsIt may be the same per-cell expression in more cells of that type. Composition and regulation are confounded in bulk by construction

Worked example: recovering the truth from §4's data

The five-gene example again, worked all the way through with median-of-ratios.

Observed counts (equal effective lengths, so length drops out):

gene    ctrl    treat
A       2000    1000
B       2000    1000
C       2000    1000
D       2000    1000
E       2000    6000

Step 1 — reference pseudo-sample. Per-gene geometric mean across the two samples:

A–D:  √(2000 × 1000) = √2,000,000  = 1414.21
E:    √(2000 × 6000) = √12,000,000 = 3464.10

Step 2 — ratio of each count to its gene's reference:

          A       B       C       D       E
ctrl    1.4142  1.4142  1.4142  1.4142  0.5774      (2000/1414.21 ; 2000/3464.10)
treat   0.7071  0.7071  0.7071  0.7071  1.7321      (1000/1414.21 ; 6000/3464.10)

Step 3 — size factor = median ratio within each sample.

ctrl  sorted: 0.5774, 1.4142, 1.4142, 1.4142, 1.4142  → median = 1.4142
treat sorted: 0.7071, 0.7071, 0.7071, 0.7071, 1.7321  → median = 0.7071

The single outlying ratio — gene E, the only gene that actually changed — sits at an end of each sorted list and cannot move the median. That is the entire robustness argument.

Step 4 — normalise (K / s):

gene    ctrl                   treat                 log2 FC
A–D     2000/1.4142 = 1414.2   1000/0.7071 = 1414.2  log2(1.000) =  0.000  ✓ unchanged
E       2000/1.4142 = 1414.2   6000/0.7071 = 8485.3  log2(6.000) =  2.585  ✓ 6-fold up

The truth is recovered exactly. Compare with total-count scaling, which reported −1.000 for four unchanged genes and +1.585 for a gene that rose 6-fold.

Step 5 — read the size factors themselves. s_treat / s_ctrl = 0.7071 / 1.4142 = 0.5, and because the counts are divided by s, the smaller size factor scales the treated counts up. The method has inferred that a treated read represents twice as much per-cell material as a control read — which is correct, since the same 10,000 reads are drawn from a treated cell containing 10,000 molecules against the control's 5,000: one molecule per read against half a molecule per read. The scale information was never in the data; it was reconstructed from the assumption that most genes did not change.

Step 6 — know when this breaks. Had genes A–D also risen 6-fold, every ratio would shift together, the median would absorb the shift, and the normalised output would be identical: all five genes flat. The data cannot distinguish "nothing changed" from "everything changed by the same factor". This is non-identifiability, not estimator error, and the only remedy is an external scale — spike-ins or a cell count.

Connections